-
According to Dr. Reddy's, $90 million will be paid upfront in cash and there will be contingent payments of up to $15 million, towards inventory and credits for certain accrued channel liabilities to be determined on the closing date.
-
Dr Reddy's Laboratories reduced the price of its cardiovascular drug Cidmus, MSN Group, launched the world’s first generic Palbociclib tablets for advanced breast cancer therapy
-
Hyderabad: Pharma major Dr Reddy’s Laboratories (DRL) reported a profit after tax of Rs 1,188 crore for the June quarter. This is an increase of Rs 108% from Rs 570.8 crore during the corresponding period last year. Its revenues during the June quarter were Rs 5,215 crore, up 6% from Rs 4,919 crore. During the […]
-
Hyderabad: Dr. Reddy’s Laboratories is conducting a job mela for science students of Dr. BR Ambedkar Open University (BRAOU) in the Department of Chemistry on the university campus on Tuesday. To attend the job mela, candidates should have 60 per cent marks in SSC, intermediate and BSc Chemistry should be one of the subjects in […]
-
New Delhi: Dr Reddy’s Laboratories on Tuesday said it has launched Sorafenib tablets, used in the treatment of various cancers, in the US market after getting approval from the US Food and Drug Administration (USFDA). “We are pleased to launch this important generic product, illustrating our continued commitment to bring affordable generic medicines to market […]
-
Hyderabad: Covid has tested and proved the credibility of the Indian pharma industry as one of the core sectors for the nation. The industry rose to the occasion by ramping up research and manufacturing to find solutions for the treatment. Pharma companies are optimistic that normalcy will return in the next one year. Speaking at […]
-
Hyderabad: Indian pharma needs to move from low-risk research and innovation to high-risk research and innovation. And that’s where the country is lagging. Investing in high-risk innovation is very capital intensive and the return on that investment is both uncertain and long-term. To aid innovation, there needs to be adequate risk capital and a different […]
-
Hyderabad: Hyderabad-based pharmaceuticals company Dr Reddy’s Laboratories reported a multi-fold increase in its consolidated net profit at Rs 706.5 crore for the quarter ended 31 December 2021, up from Rs 19.8 crore in the corresponding quarter last fiscal. The company’s revenues went up to Rs 5,319.7 crore during the third quarter compared to Rs 4,929.6 […]
-
Hyderabad: Hyderabad-based Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO), appointed Sauri Gudlavalleti as its chief operating officer. Sauri will report to the CEO & managing director, Krishna Kanumuri and drive the company’s growth as a new generation, science-driven organisation. Making the announcement, Krishna Kanumuri said, “Sauri Gudlavalleti brings with him […]
-
Hyderabad: Hyderabad-based pharmaceutical company Granules India appointed Dr KVS Ram Rao as joint managing director & CEO with effect from January 05, 2022. Dr Rao has over two decades of experience in pharmaceutical and chemical industries. Dr Ram Rao holds a bachelor’s degree in chemical engineering from Osmania University, Hyderabad, and a master’s degree & […]
-
Hyderabad: Hyderabad-based Granules India, a vertically integrated pharmaceutical company, appointed Dr Saumen Chakraborty as non-executive independent director on the Board of the company with immediate effect. Dr Chakraborty retired as the president and chief financial officer of Dr Reddy’s in November 2020 and continued to advise the company for the next one year. Commenting on […]
-
Hyderabad: Hyderabad-based Dr Reddy’s Laboratories and Prestige BioPharma have entered into a binding agreement for an exclusive partnership for the supply and commercialisation of Prestige BioPharma’s proposed trastuzumab biosimilar in select countries in Latin America and Southeast Asia. Prestige BioPharma’s trastuzumab (HD201) is a proposed biosimilar to Roche’s Herceptin and can be prescribed for the […]
-
Hyderabad: What could large enterprises like Adani Wilmar, Swiggy and JSW have in common? They all use the same HR technology platform that has been developed by three Hyderabad-based entrepreneurs. Darwinbox, which is a city-based HR technology startup have served over 600-plus clients since 2016 and has over 10 lakh users on its platform. The […]
-
Hyderabad: Hyderabad-based Dr Reddy’s Laboratories reported a consolidated profit after tax (PAT) of Rs 992 crore for the quarter, up 30 per cent from Rs 762 crore reported in the corresponding quarter last year. The company’s revenues saw a 18 per cent jump at Rs 5,763 crore for the quarter, as against Rs 4,897 crore […]
-
Hyderabad: Dr Reddy’s Laboratories created ‘Fastminar’, the world’s largest toothbrush sculpture of a body part dedicated to raising awareness of dentin hypersensitivity. Fastminar is a 40-feet structure made with approximately 80,000 toothbrushes and is located at Terna Dental College in Navi Mumbai. The monument has been certified by Guinness World Records as the largest toothbrush […]
-
Under the terms of agreement, Dr Reddy’s will receive $40 million upfront upon the closing of the transaction, followed by approval milestone payment of up to $40 million related to the CTCL (cutaneous T-cell lymphoma)
-
Reddy-Lenalidomide capsules are available in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths, each in blister packs.
-
Under the terms of agreement, Dr Reddy’s will receive $6 million (about Rs 45 crore) upfront upon closing, followed by $9 million (over Rs 65 crore) one year from closing.
-
Hyderabad firm expects that the availability of imported vaccine doses will ease from August onwards to accelerate vaccination
-
Multi-service mobile app platform brings together doctors, laboratories & diagnostics, pharmacies, and insurance for a one-stop cashless and seamless outpatient user experience
